home / stock / atnx / atnx news

ATNX News and Press, Athenex Inc. From 02/09/22

Stock Information
Company Name: Athenex Inc.
Stock Symbol: ATNX
Market: NASDAQ
Menu
ATNX ATNX Quote ATNX Short ATNX News ATNX Articles ATNX Message Board
Get ATNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ATNX - Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and ...
ATNX - Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a...

ATNX - Athenex (ATNX) Presents At 63rd Annual Meeting of ASH - Slideshow

The following slide deck was published by Athenex, Inc. in conjunction with this event. For further details see: Athenex (ATNX) Presents At 63rd Annual Meeting of ASH - Slideshow

ATNX - Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform Interim results from five evaluable patients in ANCHOR study of KUR-502 showed 80% Overall Response Rate and 60% Complete Response at lowest dose levels ...
ATNX - Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer

Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13 th , at 9:00 a.m. ET BUFFALO, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company de...

ATNX - U.K's regulatory agency validates Athenex's marketing application for Oral Paclitaxel for review

Athenex (NASDAQ:ATNX) announces that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for review. Shar...

ATNX - Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authori...
ATNX - Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients...

ATNX - Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and ...

ATNX - Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

BUFFALO, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a licensing agreement with th...
Previous 10 Next 10